Revolutionizing PCOS Treatment: How LoOoP Is Changing the Game in Women’s Health
Polycystic Ovarian Syndrome (PCOS) affects 30 million people in the U.S. alone and is a leading cause of infertility, metabolic dysfunction, and long-term health complications. Despite its profound impact, treatment options remain limited, leaving 57% of patients dissatisfied with their care. Standard interventions like hormonal contraceptives often mask symptoms rather than address the root cause, while more effective options, like electro-acupuncture, are expensive and inaccessible.
Neuraura is taking a first-in-kind approach to PCOS management, integrating bioelectronic stimulation with digital health to create an effective, accessible, and science-based solution.
The Unseen Struggle in Women’s Health
Claire Dixon has 25 years of international commercial experience, a Master’s in Engineering from Cambridge, and an MBA from Harvard. She has spent her career building and scaling businesses, but when she looked at the landscape of women’s health, she saw a glaring gap.
“The lack of investment in PCOS treatments isn’t just a medical oversight it’s a failure to recognize and prioritize women’s health” Claire says. “We know how to treat PCOS more effectively, yet the solutions that exist are expensive, inaccessible, or simply inadequate. That needs to change.”
Claire co-founded Neuraura with Pierre Wijdenes, PhD, a biomedical and human factors engineer, whose work in bioelectronic medicine laid the foundation for Neuraura’s core technology. Together, with the expertise of Dr. Elisabet Stener-Victorin, a global leader in electrostimulation for PCOS and insulin resistance, they are building a platform designed to fundamentally change how PCOS is managed.
LoOoP’s Bioelectronic Therapy
LoOoP is a non-invasive bioelectronic device that stimulates targeted nerve pathways to reduce insulin resistance, regulate hormones, and improve ovarian function. Unlike hormonal treatments, which suppress symptoms, LoOoP interacts with the body’s natural systems to address PCOS at its source.
The My LoOoP digital platform further enhances treatment by integrating personalized symptoms, tracking, and insights, and a supportive user ecosystem, ensuring people can monitor their progress and adapt their care.
“PCOS isn’t just about fertility, it’s a whole-body metabolic disorder” Claire explains. “LoOoP doesn’t just provide symptom relief. It actively shifts the body’s baseline metabolism, improves insulin sensitivity, and restores hormonal balance. That’s the real breakthrough.”
Breaking Barriers in Women’s Health Innovation
Despite the overwhelming demand for better PCOS solutions, the women’s health sector remains underfunded and deprioritized. Claire has faced this challenge firsthand while advocating for Neuraura’s work.
“One of the hardest parts of this journey is getting people to listen,” she says. “Women’s health has been overlooked for so long that we constantly have to justify why PCOS deserves attention. The data is clear. The need is massive. It’s time for the industry to catch up.”
Momentum and What’s Next
Neuraura has already secured a letter of intent for $1M in pre-sales from a major online pharmacy, developed functional prototypes, and completed human beta testing. An FDA pre-submission confirmed LoOoP as a Class II – 510(k) medical device, marking a major step toward regulatory approval. Over the next several months, the company is focused on finalizing design for manufacturing, securing FDA approval for pain management indication, getting reading for a clinical study that will expand clinical claims for insulin resistance and PCOS symptoms treatment, and launching in Canada, Europe, and additional markets.
Why mHUB
For Claire and Pierre, mHUB stood out because of its deep understanding of what it takes to bring a medical device from prototype to market. “The first time I visited mHub, I was blown away and thought to myself: where else in North America can we find a hardware accelerator specialized in health tech? We went through many incubators, but this is unique and exactly what we need,” Pierre recalls. “I didn’t want an accelerator that just talked about strategy. I needed one that understood how to get a product built, tested, and approved in the real world,” Claire explains. “mHUB has the right infrastructure and access to people who know what it takes to commercialize something like LoOoP. That’s what made it the right fit for us.”
Learn more about how mHUB supports early-stage medical device companies
mHUB has supported over 1,200 innovators by providing a hyper-resourced environment with the goal of commercializing new hardtech innovation. The mHUB community has generated more than $1.96B in revenue, launched more than 1,700 products, hired more than 6,800 employees, and raised over $2.02B in capital. To date, mHUB has invested in 54 startups across smart and sustainable manufacturing, energy tech, and medtech.
Learn more about their MedTech accelerator program and venture capital fund, mHUB Ventures.
